1
|
Guo XL, Gao YY, Yang YX, Zhu QF, Guan HY, He X, Zhang CL, Wang Y, Xu GB, Zou SH, Wei MC, Zhang J, Zhang JJ, Liao SG. Amelioration effects of α-viniferin on hyperuricemia and hyperuricemia-induced kidney injury in mice. Phytomedicine 2023; 116:154868. [PMID: 37209608 DOI: 10.1016/j.phymed.2023.154868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/12/2023] [Accepted: 05/08/2023] [Indexed: 05/22/2023]
Abstract
BACKGROUND α-Viniferin, the major constituent of the roots of Caragana sinica (Buc'hoz) Rehder with a trimeric resveratrol oligostilbenoid skeleton, was demonstrated to possess a strong inhibitory effect on xanthine oxidase in vitro, suggesting it to be a potential anti-hyperuricemia agent. However, the in vivo anti-hyperuricemia effect and its underlying mechanism were still unknown. PURPOSE The current study aimed to evaluate the anti-hyperuricemia effect of α-viniferin in a mouse model and to assess its safety profile with emphasis on its protective effect on hyperuricemia-induced renal injury. METHODS The effects were assessed in a potassium oxonate (PO)- and hypoxanthine (HX)-induced hyperuricemia mice model by analyzing the levels of serum uric acid (SUA), urine uric acid (UUA), serum creatinine (SCRE), serum urea nitrogen (SBUN), and histological changes. Western blotting and transcriptomic analysis were used to identify the genes, proteins, and signaling pathways involved. RESULTS α-Viniferin treatment significantly reduced SUA levels and markedly mitigated hyperuricemia-induced kidney injury in the hyperuricemia mice. Besides, α-viniferin did not show any obvious toxicity in mice. Research into the mechanism of action of α-viniferin revealed that it not only inhibited uric acid formation by acting as an XOD inhibitor, but also reduced uric acid absorption by acting as a GLUT9 and URAT1 dual inhibitor as well as promoted uric acid excretion by acting as a ABCG2 and OAT1 dual activator. Then, 54 differentially expressed (log2 FPKM ≥ 1.5, p ≤ 0.01) genes (DEGs) repressed by the treatment of α-viniferin in the hyperuricemia mice were identified in the kidney. Finally, gene annotation results revealed that downregulation of S100A9 in the IL-17 pathway, of CCR5 and PIK3R5 in the chemokine signaling pathway, and of TLR2, ITGA4, and PIK3R5 in the PI3K-AKT signaling pathway were involved in the protective effect of α-viniferin on the hyperuricemia-induced renal injury. CONCLUSIONS α-Viniferin inhibited the production of uric acid through down-regulation of XOD in hyperuricemia mice. Besides, it also down-regulated the expressions of URAT1 and GLUT9 and up-regulated the expressions of ABCG2 and OAT1 to promote the excretion of uric acid. α-Viniferin could prevent hyperuricemia mice from renal damage by regulating the IL-17, chemokine, and PI3K-AKT signaling pathways. Collectively, α-viniferin was a promising antihyperuricemia agent with desirable safety profile. This is the first report of α-viniferin as an antihyperuricemia agent.
Collapse
Affiliation(s)
- Xiao-Li Guo
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Yan-Yan Gao
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Ya-Xin Yang
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Qin-Feng Zhu
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Huan-Yu Guan
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Xun He
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Chun-Lei Zhang
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Ya Wang
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Guo-Bo Xu
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China; National Engineering Research Center of Miao's Medicines & Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Ministry of Education & Guizhou Provincial Key Laboratory of Pharmaceutics, Guiyang, 550004, Guizhou, China
| | - Shu-Han Zou
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China
| | - Mao-Chen Wei
- Guiyang Xintian Pharmaceutical Co., Ltd, Guiyang, 550000, Guizhou, China
| | - Jian Zhang
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China; Medicinal Bioinformatics Center, Shanghai JiaoTong University School of Medicine, 2000000, Shanghai, China
| | - Jin-Juan Zhang
- School of Basic Medical Sciences, Guizhou Medical University, Guizhou 550025, China.
| | - Shang-Gao Liao
- State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, 550025, Guizhou, China; National Engineering Research Center of Miao's Medicines & Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Ministry of Education & Guizhou Provincial Key Laboratory of Pharmaceutics, Guiyang, 550004, Guizhou, China.
| |
Collapse
|
2
|
Zou SH, Fu XM, Yu N, Tan FB, Shu TT, Li Y, Ji P, Zhang FG. [Simultaneous reconstruction of the mandible and restoration of implant supported dentition: a case report of jaw in a day in China]. Zhonghua Kou Qiang Yi Xue Za Zhi 2021; 56:1267-1270. [PMID: 34915663 DOI: 10.3760/cma.j.cn112144-20210617-00296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- S H Zou
- Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| | - X M Fu
- Department of Prosthodontics, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| | - N Yu
- Department of Prosthodontics Technology, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| | - F B Tan
- Department of Prosthodontics Technology, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| | - T T Shu
- Department of Prosthodontics Technology, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| | - Y Li
- Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| | - P Ji
- Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| | - F G Zhang
- Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Chongqing Medical University, Chongqing 401147, China
| |
Collapse
|
3
|
Huang HQ, Bai B, Gao YH, Zou DH, Zou SH, Tan H, Song YP, Li ZY, Jin J, Li W, Su H, Gong YP, Zhong MZ, Shuang YR, Zhu J, Zhang JQ, Cai Z, Teng QL, Sun WJ, Yang Y, Xia ZJ, Chen HL, Hua LM, Bao YY, Wu N. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial]. Zhonghua Xue Ye Xue Za Zhi 2019; 38:825-830. [PMID: 29166732 PMCID: PMC7364967 DOI: 10.3760/cma.j.issn.0253-2727.2017.10.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
目的 评价聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)预防淋巴瘤患者化疗后发生中性粒细胞减少症的有效性和安全性。 方法 本研究为多中心、开放、单臂、Ⅳ期临床试验。纳入410例淋巴瘤患者接受多周期化疗并预防性使用PEG-rhG-CSF。主要观察患者各化疗周期Ⅲ/Ⅳ度中性粒细胞减少症和发热性中性粒细胞减少(FN)的发生率,同时观察患者整个化疗期间抗生素的使用率。 结果 ①410例患者中,违背入选标准8例(1.95%),失访35例(8.54%),发生不良事件19例(4.63%),出现符合终止研究标准者12例(2.93%),疾病进展或复发15例(3.66%),故最终321例(78.29%)进入符合方案集。②在第1~4个治疗周期,初级预防给予PEG-rhG-CSF后,Ⅳ度中性粒细胞减少症的发生率分别为19.14%(49/256)、12.50%(32/256)、12.18%(24/197)、13.61%(20/147),FN的发生率分别为3.52%(9/256)、0.39%(1/256)、2.54%(5/197)、2.04%(3/147);次级预防给药后,Ⅳ度中性粒细胞减少症的发生率从61.54%(40/65)降至16.92%(11/65)、18.46%(12/65)、20.75%(11/53),FN的发生率从16.92%(11/65)降至1.54%(1/65)、4.62%(3/65)、3.77%(2/53)。③整个化疗期间接受抗生素治疗的受试者比例为34.39%(141/410)。④与PEG-rhG-CSF相关的不良事件发生率为4.63%(19/410),最常见的不良反应为骨痛[3.90%(16/410)]、乏力(0.49%)和发热(0.24%)。 结论 在淋巴瘤患者化疗过程中,预防性使用PEG-rhG-CSF能够有效降低化疗过程中Ⅲ/Ⅳ度中性粒细胞减少症和FN的发生率,确保淋巴瘤患者接受标准剂量化疗,提高治愈率。
Collapse
Affiliation(s)
- H Q Huang
- Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|